Skip to main content
SpringerLink
Log in

Antidysthymic Drugs (Antidepressants and Antimanics)

  • Chapter
Practitioner’s Guide to Psychoactive Drugs for Children and Adolescents

Abstract

This chapter will summarize primarily the use of antidepressants and lithium in children and adolescents. Other antimanic drugs such as carbamazepine, valproate, and clonazepam, which are all used as antiepileptics (anticonvulsants), are also discussed but further details on these drugs will be found in Chapter 12. Here, much of the discussion on the use of antidepressants will focus on their use in mood disorders (for which they were originally introduced) and on extensions of their use to anxiety disorders, attention-deficit disorders, and enuresis.1-7

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Quinn PO, Rapoport JL: One-year follow-up of hyperactive boys treated with imipramine or methylphenidate. Am J Psychiatry 132: 241–245, 1975.

    PubMed  CAS  Google Scholar 

  2. Rapoport JL, Quinn PO, Bradbard G, et al: Imipramine and methylphenidate treatments of hyperactive boys: A double-blind comparison. Arch Gen Psychiatry 30: 789–793, 1974.

    Article  PubMed  CAS  Google Scholar 

  3. Werry JS, Aman MG, Diamond E: Imipramine and methylphenidate in hyperactive children. J Child Psychol Psychiatry 21: 27–35, 1980.

    Article  PubMed  CAS  Google Scholar 

  4. Pliszka SR: Antidepressants in the treatment of child and adolescent psychopathology. J Clin Child Psychol 20: 313–320, 1991.

    Article  Google Scholar 

  5. Pliszka SR: Review article — Tricyclic antidepressants in the treatment of children with attention deficit disorder. J Am Acad Child Adolesc Psychiatry 26: 127–132, 1987.

    Article  PubMed  CAS  Google Scholar 

  6. Werry JS, Dowrick PW, Lampen EL, et al: Imipramine in enuresis — Psychological and physiological effects. J Child Psychol Psychiatry 16: 289–299, 1975.

    Article  PubMed  CAS  Google Scholar 

  7. Blackwell B, Currah J: The psychopharmacology of nocturnal enuresis, in Kolvin I, McKeith RC, Meadows SR (eds): Bladder Control and Enuresis. London, Heinemann, 1973, pp 231–257.

    Google Scholar 

  8. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 3 rev. Washington, DC, American Psychiatric Association, 1987.

    Google Scholar 

  9. Geller B, Cooper TB, Graham DL, et al: Double-blind placebo-controlled study of nortriptyline in depressed adolescents using a “fixed plasma level” design. Psychopharmacol Bull 26: 85–90, 1990.

    PubMed  CAS  Google Scholar 

  10. Kashani JH, Sherman DD: Childhood depression: Epidemiology, etiological models, and treatment implications. Integrative Psychiatry 6: 1–21, 1988.

    Google Scholar 

  11. Ryan ND: Heterocyclic antidepressants in children and adolescents. J Child Adolesc Psychopharmacol 1: 21–31, 1990.

    Article  PubMed  Google Scholar 

  12. Baldessarini RJ, Cole JO: Chemotherapy, in Nicholi AM (ed): The New Harvard Guide to Psychiatry. Cambridge, MA., Harvard University Press, 1988, pp 481–533.

    Google Scholar 

  13. Morselli PL: Drug Disposition during Development. Jamaica, NY, Spectrum Publications, 1977.

    Google Scholar 

  14. Jatlow PI: Psychotropic drug disposition during development. In Popper C (ed): Psychiatric Pharmacoscience of Children and Adolescents. Washington, DC, American Psychiatric Press, 1989, pp 29–44.

    Google Scholar 

  15. Briant RH: An introduction to clinical pharmacology, in Werry JS (ed): Pediatric Psychopharmacology: The Use of Behavior Modifying Drugs in Children. New York, Brunner/Mazel, 1978, pp 3–82.

    Google Scholar 

  16. American Hospital Formulary Service Drug Information 91. Bethesda, American Society of Hospital Pharmacists, 1991.

    Google Scholar 

  17. Facts and Comparisons. St. Louis, Facts and Comparisons, 1985.

    Google Scholar 

  18. Physicians Desk Reference. Oradell, NJ: Medical Economics Data, 1991.

    Google Scholar 

  19. Geller B, Cooper TB, Schluchter MD, et al: Child and adolescent nortriptyline single dose pharmacokinetic parameters: Final report. J Clin Psychopharmacol 7: 321–323, 1987.

    PubMed  CAS  Google Scholar 

  20. Biederman J, Baldessarini RJ, Wright V, et al: A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry 28: 777–784, 1989.

    Article  PubMed  CAS  Google Scholar 

  21. Geller G, Cooper TB, Chestnut EC, et al: Preliminary data on the relationship between nortriptyline plasma level and response in depressed children. Am J Psychiatry 143: 123–126, 1986.

    Google Scholar 

  22. Gelenberg AJ, Schoonover SC: Depression, in Gelenberg AJ, Bassuk EL, Schoonover SC (eds): The Practitioner’s Guide to Psychoactive Drugs, ed 3. New York, Plenum Press, 1991, pp 23–89.

    Google Scholar 

  23. Preskorn SH, Bupp SJ, Weller EB, et al: Plasma levels of imipramine and metabolites in 68 hospitalized children. J Am Acad Child Adolesc Psychiatry 28: 373–375, 1989.

    Article  PubMed  CAS  Google Scholar 

  24. Bernstein JG: Handbook of Drug Therapy in Psychiatry, ed 2. Boston, PSG Publishing Co, 1988.

    Google Scholar 

  25. Hollister LE: Antidepressant drugs, in Dukes MNG (ed): Meyler’s Side Effects of Drugs, VIII. New York, American Elsevier Publishing, 1975, pp 31–46.

    Google Scholar 

  26. Klein DF, Gittleman R, Quitkin F, et al: Diagnosis and Drug Treatment of Psychiatric Disorders: Adults and Children. Baltimore, Williams & Wilkins, 1980.

    Google Scholar 

  27. Klein RG, Koplewicz HS, Kanner A: Imipramine treatment of children with separation anxiety disorder. J Am Acad Child Adolesc Psychiatry 31: 21–28, 1992.

    Article  PubMed  CAS  Google Scholar 

  28. Gualtieri CT: Imipramine and children: A review and some speculations about the mechanism of drug action. Dis Nerv Syst 38: 368–375, 1977.

    PubMed  CAS  Google Scholar 

  29. Casat CD, Pleasants DZ, Schroeder DH, et al: Buproprion in children with attention deficit disorder. Psychopharmacol Bull 25: 198–201, 1989.

    PubMed  CAS  Google Scholar 

  30. Aman MG: Psychotropic drugs and learning problems — A selective review. J Learn Disabil 13: 87–97,1980.

    Article  PubMed  CAS  Google Scholar 

  31. Preskorn SH, Weller EB, Weller RA, et al: Plasma levels of imipramine and adverse effects in children. Am J Psychiatry 140: 1332–1335, 1983.

    PubMed  CAS  Google Scholar 

  32. Jackson WK, Roose SP, Glassman AH: Cardiovascular toxicity of antidepressant medications. Psychopathology 20: 64–71, 1987.

    Article  PubMed  Google Scholar 

  33. Biederman J: Sudden death in children treated with a tricyclic antidepressant. J Am Acad Child Adolesc Psychiatry 30: 495–498, 1991.

    Article  PubMed  CAS  Google Scholar 

  34. Blackwell B: Adverse effects of antidepressant drugs. Part I: Monoamine oxidase inhibitors and tricyclics. Drugs 21: 201–219, 1981.

    Article  PubMed  CAS  Google Scholar 

  35. Sovner R, DiMascio A: Extrapyramidal syndromes and other neurological side effects of psychotropic drugs, in Lipton MA, DiMascio A, Killam DF (eds): Psychopharmacology: A Generation of Progress. New York, Raven Press, 1978, pp 1021–1032.

    Google Scholar 

  36. Petti TA, Law W: Abrupt cessation of high-dose imipramine treatment in children JAMA 246: 768–769, 1981.

    Article  PubMed  CAS  Google Scholar 

  37. Preskorn SH, Weller EB, Hughes CW, et al: Depression in prepubertal children: Dexamethasone non-suppression predicts differential response to imipramine vs placebo. Psychopharmacol Bull 23: 128–133, 1987.

    PubMed  CAS  Google Scholar 

  38. Puig-Antich J, Perel JM, Lupatkin W, et al: Imipramine in prepubertal major depressive disorder. Arch Gen Psychiatry 44: 81–89, 1987.

    Article  PubMed  CAS  Google Scholar 

  39. Geller B, Cooper TB, Graham DL, et al: Pharmacokinetically-designed double-blind, placebo-controlled study of nortriptyline in 6-12 year olds with major depressive disorder. J Am Acad Child Adolesc Psychiatry 31: 34–44, 1992.

    Article  PubMed  CAS  Google Scholar 

  40. Puig-Antich J, Perel JM, Lupatkin W, et al: Plasma levels of imipramine (IMI) and desmethylimipramine (DMI), and clinical response in prepubertal major depressive disorder. A preliminary report. J Am Acad Child Psychiatry 18: 616–627, 1979.

    Article  PubMed  CAS  Google Scholar 

  41. Petti TH, Conners CK: Changes in behavioral ratings of depressed children treated with imipramine. J Am Acad Child Adolesc Psychiatry 22: 355–360, 1983.

    Article  CAS  Google Scholar 

  42. Kashani JH, Shekim WO, Reid JC: Amitriptyline in children with major depressive disorder: A double-blind crossover pilot study. J Am Acad Child Psychiatry 23: 348–351, 1984.

    Article  PubMed  CAS  Google Scholar 

  43. Ryan ND, Puig-Antich J, Cooper T, et al: Imipramine in adolescent major depression: Plasma level and clinical response. Acta Psychiatr Scand 73: 275–288, 1986.

    Article  PubMed  CAS  Google Scholar 

  44. Robbins DR, Alessi NE, Colfer MV: Treatment of adolescents with major depression: Implications of the DST and the melancholic clinical subtype. J Affect Disord 17: 99–104, 1989.

    Article  PubMed  CAS  Google Scholar 

  45. Strober M, Freeman R, Rigali J: The pharmacotherapy of depressive illness in adolescence, I: An open label trial of imipramine. Psychopharmacol Bull 26: 80–84, 1990.

    PubMed  CAS  Google Scholar 

  46. Barrickman L, Noyes R, Kuperman S, et al: Treatment of ADHD with fluoxetine: A preliminary trial. J Am Acad Child Adolesc Psychiatry 30: 762–767, 1991.

    PubMed  CAS  Google Scholar 

  47. Riddle MA, Nelson JG, Kleinman CS, et al: Sudden death in children receiving Norpramin: A review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry 30: 104–108, 1991.

    Article  PubMed  CAS  Google Scholar 

  48. Kaplan SL, Breit M, Gauthier B, et al: A comparison of three nocturnal enuresis treatment methods. J Am Acad Child Adolesc Psychiatry 28: 282–286, 1989.

    Article  PubMed  CAS  Google Scholar 

  49. Berney T, Kolvin I, Bhate SR, et al: School phobia: A therapeutic trial with clomipramine and shortterm outcome. Br J Psychiatry 138: 110–118, 1981.

    Article  PubMed  CAS  Google Scholar 

  50. Bernstein GA, Garfinkel BD, Borchardt CM: Comparative studies of pharmacotherapy for school refusal. J Am Acad Child Adolesc Psychiatry 29: 773–781, 1990.

    Article  PubMed  CAS  Google Scholar 

  51. Flament MF, Rapoport JL, Berg CJ, et al: Clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatr 42: 977–983, 1985.

    Article  PubMed  CAS  Google Scholar 

  52. Leonard HL, Swedo SE, Rapoport JL, et al: Treatment of obsessive-compulsive disorder in children and adolescents: A double-blind crossover comparison. Arch Gen Psychiatry 46: 1088–1092, 1989.

    Article  PubMed  CAS  Google Scholar 

  53. DeVeaugh J, Moroz G, Biederman J, et al: Clomipramine in child and adolescent obsessive-compulsive disorder — A multicenter trial. J Am Acad Child Adolesc Psychiatry 31: 45–49, 1992.

    Article  Google Scholar 

  54. Riddle MA, Hardin MT, King R, et al: Fluoxetine treatment of children and adolescents with Tourette’s and obsessive compulsive disorders: Preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 29: 45–48, 1990.

    Article  PubMed  CAS  Google Scholar 

  55. Swedo SE, Leonard HL, Rapoport JL, et al: A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). N Engl J Med 321: 497–501, 1989.

    Article  PubMed  CAS  Google Scholar 

  56. Weller EB, Weller RA, Carr S: Case study — Imipramine treatment of trichotillomania and coexisting depression in a seven-year-old. J Am Acad Child Adolesc Psychiatry 28: 952–953, 1989.

    Article  PubMed  CAS  Google Scholar 

  57. Ponto LB, Perry PJ, Liskow BI, et al: Tricyclic antidepressant and monoamine oxidase inhibitor combination therapy. Am J Hosp Pharm 34: 954–961, 1977.

    PubMed  CAS  Google Scholar 

  58. Briant RH, Reid JL, Dollery CT: Interaction between clonidine and desipramine in man. Br Med J 1: 522–523, 1973.

    Article  PubMed  CAS  Google Scholar 

  59. Mitchel L Jr, Arias L, Oates JA: Antagonism of hypertensive action of guanethidine sulfate by desipramine hydrochloride. JAMA 202: 973–976, 1967.

    Article  Google Scholar 

  60. Gram LF: Effects of perphenazine on imipramine metabolism in man. Psychopharmacol Commun 1: 165–175, 1975.

    PubMed  CAS  Google Scholar 

  61. Perucca E, Richens A: Interactions between phenytoin and imipramine. Br J Clin Pharmacol 4: 485–486, 1977.

    Article  PubMed  CAS  Google Scholar 

  62. Ballinger BR, Presly A, Reid AH: The effects of hypnotics on imipramine treatment. Psychopharmacologia 39: 267–274, 1974.

    Article  PubMed  CAS  Google Scholar 

  63. Wharton RN, Perel JM, Dayton PG, et al: A potential clinical use of methylphenidate with tricyclic antidepressants. Am J Psychiatry 127: 1619–1625, 1971.

    PubMed  CAS  Google Scholar 

  64. Puig-Antich J, Ryan ND, Rabinovich H: Affective disorders in childhood and adolescence, in Wiener J (ed): Diagnosis and Psychopharmacology of Childhood and Adolescent Disorders. New York, John Wiley & Sons, 1985.

    Google Scholar 

  65. Baldessarini RJ: Drugs and the treatment of psychiatric disorders, in Gilman AG, Rall TW, Nies AS, et al (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics, ed 8. New York, Pergamon Press, 1990, pp 418–422.

    Google Scholar 

  66. Green WH: Child and Adolescent Clinical Psychopharmacology. Baltimore, Williams & Wilkins, 1991, pp 134–137.

    Google Scholar 

  67. Akiskal HS: Mood disturbances, in Winokur G, Clayton P (eds): The Medical Basis of Psychiatry. Philadelphia, WB Saunders Co, 1986.

    Google Scholar 

  68. Ryan N, Puig-Antich J, Rabinovich H, et al: MAOIs in adolescent major depression unresponsive to tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry 27: 755–758, 1988.

    Article  PubMed  CAS  Google Scholar 

  69. Zametkin AJ, Rapoport JL: Noradrenergic hypothesis of attention deficit disorder with hyperactivity: A critical review, in Meltzer HY (ed): Psychopharmacology: The Third Generation of Progress. New York, Raven Press, 1987.

    Google Scholar 

  70. Zametkin A, Rapoport JL, Murphy DL, et al: Treatment of hyperactive children with monoamine oxidase inhibitors: I. Clinical efficacy. Arch Gen Psychiatry 42: 962–966, 1985.

    Article  PubMed  CAS  Google Scholar 

  71. Weller EB, Weller RA: Mood disorders, in Lewis M (ed): Child and Adolescent Psychiatry: A Comprehensive Textbook. Baltimore, Williams & Wilkins, 56: 646–664, 1991.

    Google Scholar 

  72. Varanka TM, Weller RA, Weller EB, et al: Lithium treatment of manic episodes with psychotic features in prepubertal children. Am J Psychiatry 145: 1557–1559, 1988.

    PubMed  CAS  Google Scholar 

  73. Weller RA, Weller EB, Tucker SG, et al: Mania in prepubertal children: Has it been underdiagnosed? J Affect Dis 11: 151–154, 1986.

    Article  PubMed  CAS  Google Scholar 

  74. Goodwin FK, Jamison KR: Manic-Depressive Illness. New York, Oxford University Press, 1990.

    Google Scholar 

  75. Carlson GA, Kashani JH: Manic symptoms in a non-referred adolescent population. J Affect Dis 15: 219–226, 1988.

    Article  PubMed  CAS  Google Scholar 

  76. Robins LN, Helzer JR, Weissman MM, et al: Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 41: 949–958, 1984.

    Article  PubMed  CAS  Google Scholar 

  77. Cade JF: Lithium salts in the treatment of psychotic excitement. Med J Aust 11: 349–352, 1949.

    Google Scholar 

  78. Prien RF, Caffey EM, Klett CJ: Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry 28: 337–341, 1973.

    Article  PubMed  CAS  Google Scholar 

  79. Rapoport JL, Mikkelsen EJ, Werry JS: Antimanic, antianxiety, hallucinogenic and miscellaneous drugs, in Werry JS (ed): Pediatric Psychopharmacology: The Use of Behavior Modifying Drugs in Children. New York, Brunner/Mazel, 1978, pp 316–355.

    Google Scholar 

  80. Jefferson JW: The use of lithium in childhood and adolescence: An overview. JClin Psychiatry 43: 174–177, 1982.

    CAS  Google Scholar 

  81. Schou M: Lithium in psychiatric therapy and prophylaxis. J Psychiatr Res 6: 67–95, 1971.

    Article  Google Scholar 

  82. Jefferson JW, Greist JH, Ackerman DL, et al: Mechanism of action, in Jefferson JW, Greist JH, Ackerman DL, et al (eds): Lithium Encyclopedia for Clinical Practice, ed 2. Washington, DC, American Psychiatric Press, 1987, pp 436–441.

    Google Scholar 

  83. Carlson GA: Bipolar disorders in children and adolescents, in Garfinkel B, Carlson G, Weller E (eds): Psychiatric Disorders in Children and Adolescents. Philadelphia, WB Saunders Co, 1990, pp 21–36.

    Google Scholar 

  84. Amdisen A, Carson S: Lithium, in Evans WE, Schentag JJ, Jusko WJ (eds): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Spokane, Wash: Applied Therapeutics, 1986, pp 97–100.

    Google Scholar 

  85. Perry PJ, Alexander B, Liskow BI: Antimanic agents, in Perry PJ, Alexander B, Liskow BI (eds): Psychotropic Drug Handbook, ed 5. Cincinnati, Harvey Whitney Books, 1988, pp 85–112.

    Google Scholar 

  86. Appleton WS: Pharmacological treatment for affective disorders, in Appleton WS (ed): Practical Clinical Psychopharmacology, ed 3. Baltimore, Williams & Wilkins, 1988, pp 81–150.

    Google Scholar 

  87. Fetner HH, Geller B: Lithium and tricyclic antidepressants. Psychiatr Clin North Am 15: 223–241, 1992.

    PubMed  CAS  Google Scholar 

  88. Platt JE, Campbell M, Green WH, et al: Cognitive effects of lithium carbonate and haloperidol in treatment-resistant aggressive children. Arch Gen Psychiatry 41: 657–662, 1984.

    Article  PubMed  CAS  Google Scholar 

  89. Campbell M, Schulman D, Rapoport J: The current status of lithium therapy in child and adolescent psychiatry. J Am Acad Child Psychiatry 14: 717–729, 1978.

    Google Scholar 

  90. Campbell M, Cohen IL, Small AM: Drugs in aggressive behavior. J Am Acad Child Psychiatry 21: 107–117, 1982.

    Article  PubMed  CAS  Google Scholar 

  91. Campbell M, Fish B, Korein J, et al: Lithium and chlorpromazine: A controlled crossover study of hyperactive severely disturbed young children. J Autism Child Schizophr 2: 234–263, 1972.

    Article  PubMed  CAS  Google Scholar 

  92. Gram LF, Rafaelson OJ: Lithium treatment of psychotic children and adolescents. Acta Psychiatr Scand 48: 253–260, 1972.

    Article  PubMed  CAS  Google Scholar 

  93. Carlson GA, Rapport MD, Kelly KL, et al: The effect of methylphenidate and lithium on attention and activity level. J Am Acad Child Adolesc Psychiatry 31: 262–270, 1992.

    Article  PubMed  CAS  Google Scholar 

  94. Campbell M, Small AM, Green WH, et al: Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 41: 650–656, 1984.

    Article  PubMed  CAS  Google Scholar 

  95. Campbell M, Green WH, Deutsch SI: Child and Adolescent Psychopharmacology. Beverly Hills, Sage Publications, 1985.

    Google Scholar 

  96. Deandrea D, Walker N, Nehlmauer M, et al: Dermatological reactions to lithium: A critical review of the literature. J Clin Psychopharmacol 2: 199–204, 1982.

    Article  PubMed  CAS  Google Scholar 

  97. Jefferson JW: Lithium and tetracycline. Br J Dermatol 107: 370, 1982.

    Article  Google Scholar 

  98. Herskowitz J: Developmental toxicology, in Popper C (ed): Psychiatric Pharmacosciences of Children and Adolescents. Washington, DC, American Psychiatric Press, 1987.

    Google Scholar 

  99. Birch NJ, Horsman A, Hullin RP: Lithium, bone and body weight studies in long-term treated patients and in the rat. Neuropsychobiology 86–92, 1982.

    Google Scholar 

  100. Wilson WH, Jefferson JW: Thyroid disease, behavior and psychopharmacology. Psychosomatics 26: 481–492,1985.

    Article  PubMed  CAS  Google Scholar 

  101. Vendborg PB, Bech P, Rafaelsen OJ: Lithium treatment and weight gain. Acta Psychiatr Scand 53: 139–147,1976.

    Article  Google Scholar 

  102. Vestergaard P, Amdisen A, Schou M: Clinically significant side effects of lithium treatment: A survey of 237 patients in long-term treatment. Acta Psychiatr Scand 62: 193–200, 1980.

    Article  PubMed  CAS  Google Scholar 

  103. Kirk L, Baastrup PC, Schou M: Propranolol treatment of lithium-induced tremor. Lancet 2: 106–107, 1973.

    Google Scholar 

  104. Reisberg B, Gershon S: Side effects associated with lithium therapy. Arch Gen Psychiatry 36:879–887,1979.

    Article  PubMed  CAS  Google Scholar 

  105. Joffe RT, Kellner CG, Post RM, et al: Lithium increases in platelet count (letter). N Engl J Med 311: 674–675, 1984.

    PubMed  CAS  Google Scholar 

  106. Wood IK, Parmelee DX, Foreman JW: Lithium-induced nephrotic syndrome. Am J Psychiatry 146: 84–87, 1989.

    PubMed  CAS  Google Scholar 

  107. Khandelwal SK, Varma VK, Marthy RS: Renal function in children receiving long-term lithium prophylaxis. Am J Psychiatry 141: 278–279, 1984.

    PubMed  CAS  Google Scholar 

  108. Strober M, Carlson GA: Bipolar illness in adolescents with major depression: Clinical, genetic, and psychopharmacologic predictors in a 3 to 4-year prospective follow up investigation. Arch Gen Psychiatry 39: 549–555, 1982.

    Article  PubMed  CAS  Google Scholar 

  109. Akiskal HS, Down SJ, Jordan P, et al: Affective disorders in referred children and younger siblings of manic depressives. Arch Gen Psychiatry 42: 996–1004, 1985.

    Article  PubMed  CAS  Google Scholar 

  110. Delong R, Aldershof AL: Long-term experience with lithium treatment in childhood: Correlation with clinical diagnosis. J Am Acad Child Adolesc Psychiatry 26: 389–394, 1987.

    Article  PubMed  CAS  Google Scholar 

  111. Youngerman J, Canino IA: Lithium carbonate use in children and adolescents: A survey of the literature. Arch Gen Psychiatry 35: 216–224, 1978.

    Article  PubMed  CAS  Google Scholar 

  112. Lena B: Lithium treatment of children and adolescents, in Johnson FN (ed): Handbook of Lithium Therapy. Lancaster, PA, MTP Press, pp 405–413, 1980.

    Chapter  Google Scholar 

  113. Strober M, Morrel W, Lampert C, et al: Relapse following discontinuation of lithium maintenance therapy in adolescents with bipolar I illness. A naturalistic study. Am J Psychiatry 147: 457–461, 1990.

    PubMed  CAS  Google Scholar 

  114. Werry JS, McClellan JM, Chard L: Childhood and adolescent schizophrenic, bipolar and schizoaffective disorders. A clinical and outcome study. J Am Acad Child Adolesc Psychiatry 30: 457–465, 1991.

    Article  PubMed  CAS  Google Scholar 

  115. Stewart MA, Beblois CS, Meardon J, et al: Aggressive conduct disorder of children: The clinical picture. J Nerv Ment Dis 16: 604–610, 1980.

    Article  Google Scholar 

  116. Campbell M: Psychopharmacology, in Noshpitz JD (ed): Basic Handbook of Child Psychiatry. New York, Basic Books, 1979, vol 3, pp 376–409.

    Google Scholar 

  117. Greenhill L, Rieder R, Werda P, et al: Lithium carbonate in the treatment of hyperactive children. Arch Gen Psychiatry 2: 636–640, 1973.

    Article  Google Scholar 

  118. Licamele WL, Goldberg RL: The concurrent use of lithium and methylphenidate in a child. J Am Acad Child Adolesc Psychiatry 28: 785–787, 1989.

    Article  PubMed  CAS  Google Scholar 

  119. Ryan N, Meyer VA, Dachille S, et al: Lithium antidepressant augmentation in TCA-refractory depression in adolescents. J Am Acad Child Adolesc Psychiatry 27: 371–376, 1988.

    Article  PubMed  CAS  Google Scholar 

  120. Strober M, Freeman R, Rigali J, et al: The pharmacotherapy of depressive illness in adolescence: II. Effects of lithium augmentation in nonresponders to imipramine. J Am Acad Child Adolesc Psychiatry 31: 16–20, 1992.

    Article  PubMed  CAS  Google Scholar 

  121. Weller EB, Weller RA, Fristad MA: Lithium dosage guide for prepubertal children: A preliminary report. J Am Acad Child Adolesc Psychiatry 25: 92–95, 1986.

    Article  CAS  Google Scholar 

  122. Campbell M, Small AM, Green WM, et al: Lithium and haloperidol in hospitalized aggressive children. Psychopharmacol Bull 1: 125–130, 1982.

    Google Scholar 

  123. Siassi I: Lithium treatment of impulsive behavior in children. J Clin Psychiatry 43: 42–44, 1982.

    Google Scholar 

  124. Persson G: Lithium side effects in relation to dose and to levels of lithium in plasma. Acta Psychiatr Scand 51: 285–288, 1975.

    Google Scholar 

  125. Jefferson JW: Treating affective disorders in the presence of cardiovascular disease. Psychiatr Clin North Am 6: 141–155, 1983.

    PubMed  CAS  Google Scholar 

  126. Lippmann S, Wagemaker H, Tucker D: A practical approach to management of lithium concurrent with hyponatremia, diuretic therapy and/or chronic renal failure. J Clin Psychiatry 42: 304–306, 1981.

    PubMed  CAS  Google Scholar 

  127. Tyrer SP: Lithium in the treatment of mania. J Affect Dis 8: 251–257, 1985.

    Article  PubMed  CAS  Google Scholar 

  128. Jefferson JW: Serum lithium levels and long-term diuretic use. JAMA 241: 1134–1136, 1979.

    Article  PubMed  CAS  Google Scholar 

  129. Shulka S, Godwin CD, Long LE, et al: Lithium-carbamazepine neurotoxicity and risk factors. Am J Psychiatry 141: 1604–1606, 1984.

    Google Scholar 

  130. Perry PJ, Calloway RA, Cook B, et al: Theophylline precipitated alterations in lithium clearance. Acta Psychiatry Scand 69: 528–537, 1984.

    Article  CAS  Google Scholar 

  131. Ballenger JC, Post RM: Carbamazepine in manic-depressive illness: A new treatment. Am J Psychiatry 137: 782–790, 1980.

    PubMed  CAS  Google Scholar 

  132. Stromgrew LS, Boiler S: Carbamazepine in treatment and prophylaxis of manic-depressive disorder. Psychiatry Dev 4: 349–367, 1985.

    Google Scholar 

  133. Hsu LK: Lithium-resistant adolescent mania. J Am Acad Child Psychiatry 25: 280–283, 1986.

    Article  PubMed  CAS  Google Scholar 

  134. Trimble MR: Anticonvulsants in children and adolescents. J Child Adolesc Psychopharmacol 1:107–124, 1990.

    Article  PubMed  CAS  Google Scholar 

  135. Levy R, Pitlick WH: Carbamazepine: Interaction with other drugs, in Woodbury DM, Penry JD, Pippenger CE (eds): Antiepileptic Drugs. New York, Raven Press, 1982, pp 497–505.

    Google Scholar 

  136. Livingston S, Pauli L, Berman W: Carbamazepine in epilepsy. Nine year follow-up with special emphasis on untoward reaction. Dis Nerv Syst 35: 103–107, 1974.

    PubMed  CAS  Google Scholar 

  137. Killam FM, Fromm GH: Carbamazepine in the treatment of neuralgia: Use and side effects. Arch Neurol 19: 129–136, 1968.

    Article  Google Scholar 

  138. Rall TW, Schleifer LS: Drugs effective in the therapy of the epilepsies, in Gilman AG, Rall TW, Nies AS, et al (eds): The Pharmacological Basis of Therapeutics, ed 8. New York, Pergamon Press, 1990, pp 436–462.

    Google Scholar 

  139. Calabrese J, Delucchi G: Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 47: 431–434, 1990.

    Google Scholar 

  140. McElroy SL, Keck P, Pope HG: Sodium valproate: Its use in primary psychiatric disorders. J Clin Psychopharmacol 7: 16–24, 1987.

    PubMed  CAS  Google Scholar 

  141. Dreifuss FE, Santilli N, Langer DH, et al: Valproic acid hepatic fatalities: A retrospective review. Neurology 37: 379–385, 1987.

    Article  PubMed  CAS  Google Scholar 

  142. Pope H, McElroy S, Keck P, et al: Valproate in the treatment of acute mania. Arch Gen Psychiatry 48: 62–68, 1991.

    Article  PubMed  Google Scholar 

  143. Janicak PG, Bishes RA: Advances in the treatment of mania and other acute psychotic disorders. Psychiatr Ann 17: 145–149, 1987.

    Google Scholar 

  144. Biederman J: The diagnosis and treatment of adolescent anxiety disorders. J Clin Psychiatry 51 (suppl): 20–26, 1990.

    PubMed  Google Scholar 

  145. Biederman J: Clonazepam in the treatment of prepubertal children with panic-like symptoms. J Clin Psychiatry 48: 38–41, 1987.

    PubMed  Google Scholar 

  146. Moriselli PL, Bianchetti G, Dugas M: Therapeutic drug monitoring of psychotropic drugs in children. Pediatr Pharmacol 3: 149–156, 1983.

    Google Scholar 

  147. deGatta MF, Garcia MJ, Acosta A, et al: Monitoring of serum levels of imipramine and desipramine and individuation of dose in enuretic children. Ther Drug Monit 6: 438–443, 1984.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. John O. Viesselman M.D. (Private Practitioner)

    Present address: , Ventura, California, 93003

Authors and Affiliations

  1. Department of Psychiatry, The Ohio State University, Columbus, Ohio, 43210, USA

    John O. Viesselman M.D. (Private Practitioner), Shahnour Yaylayan M.D., Elizabeth B. Weller M.D. & Ronald A. Weller M.D.

Authors
  1. John O. Viesselman M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shahnour Yaylayan M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elizabeth B. Weller M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ronald A. Weller M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Auckland, Auckland, New Zealand

    John S. Werry M.D. (Emeritus Professor of Psychiatry) (Emeritus Professor of Psychiatry)

  2. The Nisonger Center for Mental Retardation and Developmental Disabilities, The Ohio State University, Columbus, Ohio, USA

    Michael G. Aman Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media New York

About this chapter

Cite this chapter

Viesselman, J.O., Yaylayan, S., Weller, E.B., Weller, R.A. (1993). Antidysthymic Drugs (Antidepressants and Antimanics). In: Werry, J.S., Aman, M.G. (eds) Practitioner’s Guide to Psychoactive Drugs for Children and Adolescents. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2884-5_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2884-5_9

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-306-44389-3

  • Online ISBN: 978-1-4615-2884-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation